Home / 2018 / February (page 2)

Monthly Archives: February 2018

The Coming Debate on Closed-Loop Insulin Delivery Systems

Guest Post by David Kliff, Editor, Diabetic Investor

As I left Vienna after attending the 11th International Conference on Advanced Technologies & Treatments for Diabetes, my thoughts turned to what does this all mean, what was the most significant takeaway? By far the most significant development coming out of ATTD is the long quest to have a REAL closed-loop insulin delivery system is no longer a pipe dream. This is going to happen and for once I believe it will happen in my lifetime. It is difficult to overstate the power of the data I witnessed. The reality here is that some very smart people have come a very long way.

Read More »

Reducing Heart Risk

According to a recent study, which one of the following diabetes therapies carries a lower risk for adverse cardiovascular (CV) events? 1. Nonspecific, long-acting sulfonylureas (eg, glyburide and glimepiride) 2. Specific, short-acting sulfonylureas (eg, glipizide, tolbutamide) 3. CV risk does not differ between these agents Follow the link for the answer.

Read More »

Jim McDermott Transcript

This Exclusive Interview transcript allows you to read the full conversation between Dr. Jim McDermott and Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA. Dr. McDermott discusses the SGLT-2 research at AstraZeneca, including the CVD-REAL  large outcomes trial.

Read More »